Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops
03:17pm, Thursday, 03'rd Apr 2025
Researchers investigated whether the shingles (herpes zoster) vaccine can help prevent dementia. Previous studies suggest that certain herpes viruses may contribute to dementia, and vaccines might hav
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs
UK pharma escapes worst of Trump tariffs (for now) but uncertainty may keep pressure on shares
09:33am, Thursday, 03'rd Apr 2025
International pharma stocks GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) may have dodged a bullet under Donald Trump's sweeping new tariff regime, according to analysts at Shore Capital
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are adv
GSK plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
07:30am, Thursday, 03'rd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the
GSK Investors Have Opportunity to Lead GSK plc Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
07:00am, Thursday, 03'rd Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK pl
Shareholders that lost money on GSK plc(GSK) should contact The Gross Law Firm about pending Class Action - GSK
05:45am, Thursday, 03'rd Apr 2025
NEW YORK , April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
06:00pm, Wednesday, 02'nd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the
GSK Deadline: GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit
05:25pm, Wednesday, 02'nd Apr 2025
NEW YORK , April 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5,
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Shareholders that lost money on GSK plc (GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
02:45pm, Wednesday, 02'nd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between Febr
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Wednesday, 02'nd Apr 2025
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
